LONGEVITY & CELLULAR HEALTH / FAQ
Straight Answers, No Padding
Direct, citation-anchored answers to the questions readers most often bring to epitalon and MOTS-c.
What is epitalon?
Epitalon is a synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly, abbreviated AEDG) built to match the amino-acid composition of epithalamin, an extract of the bovine pineal gland. It is studied mainly for two things: activating telomerase, an enzyme involved in maintaining the protective caps on chromosomes, and stimulating melatonin production in the pineal gland. It is not an approved drug anywhere in the West; it is sold and studied as a research chemical, and its physico-chemical characterization in the literature is still described as limited [1].
What are the benefits of epitalon according to research?
In cell and animal studies, epitalon has been shown to induce telomerase activity and telomere elongation in human fibroblast cultures, stimulate melatonin-synthesis enzymes in rat pinealocyte culture, and — in a long observational human cohort — was associated with a 1.6-to-4.1-fold reduction in mortality depending on the regimen studied [2][3][4][5]. Community-reported benefits — better sleep, steadier circadian rhythm, more daytime energy, a general sense of well-being — are widely described in longevity forums, but this is anecdotal, not clinical evidence, and a very common report in the same communities is no noticeable effect at all.
What is the recommended dosage of epitalon in research protocols?
This site does not publish a recommended dosage for epitalon, in a research protocol or any other context. No dose-response relationship has been established in controlled human research — the most-cited human study is a long observational cohort, not a dose-ranging trial [5] — and a 2025 review of the compound notes that its physico-chemical characterization remains limited [1]. Any specific number circulating online is an extrapolation, a habit, or marketing, not a clinical finding, and this desk will not repeat it as guidance.
How often should epitalon be cycled, once or twice a year?
This site does not recommend a cycling schedule for epitalon, twice a year or otherwise. There is no clinical trial establishing an optimal interval for use. The once- or twice-yearly convention that circulates in longevity communities is a self-directed practice passed around informally, not a finding from the published research record [1]. Stating that convention exists is different from endorsing it, and this desk does the former, not the latter.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome. Its best-characterized action is inhibiting part of the folate cycle, which activates AMPK, a cellular energy-sensing switch that improves glucose uptake and insulin sensitivity, primarily in skeletal muscle [11]. Under metabolic stress it also translocates to the cell nucleus to help regulate stress-response genes [10], and a 2024 study identified casein kinase 2 as a direct molecular binding target, with tissue-specific effects in muscle versus fat [6].
What are the negative side effects of MOTS-c?
There is no established human side-effect profile for MOTS-c, because there is no completed human clinical trial of it. The strongest human data point — a 94-person hemodialysis cohort — measured an association between circulating MOTS-c levels and mortality/cardiovascular risk, not the effects of administering the peptide [7]. Community-reported anecdotal side-effect data of the kind available for epitalon simply is not present in the research record for MOTS-c yet, and this site will not invent a list to fill that gap.
Is MOTS-c legal to buy?
MOTS-c is not FDA-approved for any human use; it is sold and studied only as a research chemical, and purity, identity, and sterility are not regulated the way a pharmaceutical would be. Separately from that research-chemical status, anti-doping authorities including USADA and WADA treat MOTS-c as a prohibited substance in elite sport, so athletes bound by those rules risk sanctions for use. Legal status for research-chemical sale can vary by jurisdiction and is not a substitute for checking local regulation directly.
How often do you inject MOTS-c?
This site does not provide an injection schedule for MOTS-c. There is no completed human clinical trial establishing a dosing frequency, and no published human pharmacokinetic data — no measured half-life, no dose-response curve — exists to base one on [8]. Any frequency described online reflects informal community practice, not a research finding, and this desk does not repeat it as a recommendation.